Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTUITION: Aflibercept for Idiopathic Choroidal Neovascularization
NCT02257502Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Jul 2015
- Primary completion
- Jul 2019
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in choroidal neovascularization (CNV), sponsored by Hospices Civils de Lyon. Primary endpoint: Mean change in best-corrected visual acuity at 52 weeks. Started Jul 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT02257502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02257502.